Skip to main content

Table 3 Comparison of F-based group vs. G-based group

From: Gemcitabine-based versusfluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study

Characteristics F Group (%) G Group (%) P value
Total Number 144 99  
Median age, years (range) 60 (range 29–80) 61 (range 26–81)  
Sex    0.831
   Male 95 (66.0) 64 (64.6)  
   Female 49 (34.0) 35 (35.4)  
ECOG performance status at baseline    0.06
   0 – 1 132 (91.7) 83 (83.8)  
   ≥ 2 12 (8.3) 16 (16.2)  
Disease    0.966
   Intrahepatic cholangiocarcinoma 54 (37.5) 38 (38.4)  
   Gallbladder cancer 42 (29.2) 30 (30.3)  
   Extrahepatic bile duct cancer 36 (25.0) 22 (22.2)  
   Ampulla of Vater carcinoma 12 (8.3) 9 (9.1)  
Relapsed disease 51 (35.4) 33 (33.3) 0.737
Biliary stent or bypass during treatment 31 (21.5) 33 (33.3) 0.04
Disease associated infection during treatment (cholangitis, liver abscess) 31 (21.5) 31 (31.3) 0.086
Duration from off chemotherapy to death 3.5 months (95% CI, 2.9–4.0) 3.3 months (95% CI, 2.2–4.3) 0.752
  1. ECOG, Eastern Cooperative Oncology Group; F, fluoropyrimidines; G, gemcitabine; CI, confidence interval